PMZ-1620 along with standard treatment

DRUG2 trials

Sponsors

Pharmazz, Inc.

Conditions

Acute Spinal Cord InjuryAcute StrokeCerebral Ischemia

Phase 2

PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients

CompletedNCT04046484

Pharmazz, Inc.Acute Stroke, Cerebral Ischemia

Start: 2018-01-19End: 2019-06-30Updated: 2025-05-12

PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

RecruitingNCT04054414

Pharmazz, Inc.Acute Spinal Cord Injury

Start: 2019-01-10End: 2026-07-31Target: 40Updated: 2025-07-04

Related Papers

Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

Drugs2024-11-153 citations

Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke.

2021-01-1129 citations

Abstract WP161: Sovateltide Promotes Regeneration and Functional Recovery of Ischemic Brain by Improving Mitochondrial Function

Stroke2020-02-012 citations

Abstract 14: A Randomized Study to Determine Efficacy of Sovateltide (PMZ-2010) in Patients With Acute Cerebral Ischemic Stroke

Stroke2020-02-01